Anders Jack 4

What Happened

• Anders Jack, Chief Financial Officer of Revolution Medicines (RVMD), sold 2,753 shares on 2026-03-17 at $99.48 per share for proceeds of about $273,870. The filing classifies the transaction as a sale and indicates it was made under a pre-established Rule 10b5-1 plan to cover tax withholding related to RSU vesting.

Key Details

• Transaction date and price: 2026-03-17, 2,753 shares at $99.48 each.
• Total proceeds: approximately $273,870.
• Filing date: 2026-03-19 (timely; filed within two business days).
• Ownership after transaction: filing notes beneficial ownership includes 56,600 RSUs (footnote F2).
• Footnotes: F1 — sale made pursuant to a 10b5-1 instruction letter adopted May 31, 2023 to satisfy tax withholding on RSU vesting after July 15, 2023; F2 — includes 56,600 RSUs.

Context

• This was a sale to satisfy tax withholding under a 10b5-1 plan (routine and not an explicit endorsement or negative signal about the company). Sales under 10b5-1 plans are pre-scheduled and common following RSU vesting; they typically reflect tax or portfolio-management needs rather than real-time views on the stock.